HAVCR1 and type 2 diabetes mellitus: In persons with T2D, treatment with canagliflozin decreased the plasma levels of inflammatory and fibrosis biomarkers, including kidney injury molecule-1 (KIM-1) and tumor necrosis factor receptors TNFR-1 and TNFR-2, when compared to placebo [39].